Table 4.

HRs (with 95% CIs) of risk of first serious infection among persons with psoriasis or psoriatic arthritis, by drug class

	Unadjusted	Adjusted for propensity score and imbalanced covariates
Total cohort
IL-17 vs TNF	0.86 (0.58 to 1.27)	0.89 (0.48 to 1.66)
IL-12/23 vs TNF	0.55 (0.37 to 0.80)	0.59 (0.39 to 0.90)
IL-17 vs IL-12/23	1.53 (0.94 to 2.51)	1.12 (0.62 to 2.03)
Psoriasis
IL-17 vs TNF	0.76 (0.50 to 1.18)	0.73 (0.36 to 1.45)
IL-12/23 vs TNF	0.53 (0.35 to 0.81)	0.59 (0.38 to 0.92)
IL-17 vs IL-12/23	1.42 (0.83 to 2.41)	1.01 (0.53 to 1.92)
Psoriatic arthritis
IL-17 vs TNF	0.83 (0.47 to 1.47)	0.67 (0.25 to 1.73)
IL-12/23 vs TNF	0.74 (0.41 to 1.34)	0.74 (0.40 to 1.36)
IL-17 vs IL-12/23	1.10 (0.52 to 2.35)	1.23 (0.50 to 3.01)
Biologic-naive
IL-17 vs TNF	1.45 (0.70 to 3.00)	2.02 (0.94 to 4.33)
IL-12/23 vs TNF	0.41 (0.22 to 0.76)	0.46 (0.23 to 0.89)
IL-17 vs IL-12/23	3.63 (1.44 to 9.12)	3.34 (1.10 to 10.12)
Biologic experienced
IL-17 vs TNF	0.68 (0.42 to 1.12)	0.72 (0.40 to 1.32)
IL-12/23 vs TNF	0.62 (0.37 to 1.04)	0.72 (0.42 to 1.26)
IL-17 vs IL-12/23	1.05 (0.59 to 1.90)	0.92 (0.49 to 1.74)

IL, interleukin; PsA, psoriatic arthritis; PsO, psoriasis; TNF, tumour necrosis factor.